Skip to main content
Contact Us
Subscribe
E-Edition
53°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Inhibikase Therapeutics
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
November 14, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
October 21, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
October 09, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
August 14, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
August 07, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
June 17, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
June 05, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
May 20, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
May 15, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
May 15, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
May 09, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
April 18, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
April 03, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
March 27, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
March 07, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
February 28, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
February 07, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
January 29, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
January 16, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
December 19, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
December 04, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
November 14, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
November 07, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
November 07, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment
October 16, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
October 04, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Tickers
IKT
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
September 20, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.